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Summary An in vitro autophosphorylation assay has been used to demonstrate that there is considerable
variation in met associated protein kinase among human tumour cell lines. Of particular note was the very
high level of autophosphorylation of the 140kD met protein (pl40ret) in experiments with A431 human
cervical carcinoma cells. In contrast in experiments with Daoy human medulloblastoma cells we failed to
detect phosphorylation of pl40oe'; instead a high level of phosphorylation of a 132kD protein was observed.
To help understand the basis for the variation in kinase activity and to learn more about the structure of the
mature met protein we have analysed pl40met in SDS-polyacrylamide gels under non-reducing conditions.
Under these conditions the met protein had an apparent molecular weight of 165,000 indicating that the
mature met protein may exist as an a,B complex in which p140"e' (designated the fi subunit) is joined by
disulphide bonds to a smaller, 25 kD, a-chain. We have identified a potential proteolytic cleavage site with the
sequence Lys-Arg-Lys-Lys-Arg-Ser at amino acids 303-308 in the human met protein that may account for
cleavage of the met protein into a and ,B subunits.
The human and mouse met protooncogenes encode proteins
that have the characteristics of growth factor receptors.
Thus, the 1408 amino acid human met protein (Park et al.,
1987) can be divided into several putative domains, including
an intracellular protein tyrosine kinase (PTK) domain, a
transmembrane domain and a 926 amino acid extracellular
domain that possesses a cysteine-rich region. An activa-ed
form of the met gene that is present in the chemically-
transformed human cell line (MNNG-HOS) was originally
detected by its ability to transform NIH3T3 mouse fibro-
blasts in DNA transfection experiments (Cooper et al.,
1984a,b). Activation of met involves a chromosomal re-
arrangement in which the regions of the met gene encoding
the transmembrane and extracellular domain are replaced
by a portion ofan unrelated gene that has been designated tpr
(Park et al., 1986a; Tempest et al., 1986a). The chimaeric
gene is transcribed to produce a 5.0kb hybrid mRNA that is
in turn translated to form a fusion protein. DNA sequence
analysis of cDNA clones prepared from transcripts of the
activated human met gene reveal that all of the met PTK
domain is retained in the product of the activated gene and
that the region of the fusion protein encoded by the tpr gene
exhibits weak homology to laminin Bi (Chan et al., 1987).
Alterations of met were also observed in lines of sponta-
neously transformed mouse fibroblasts where a modest (4-8
fold) amplification of the protooncogene is accompanied by
dramatic (50-100 fold) increase in the level of an 8.5 kb met
transcript (Cooper et al., 1986).
Northern analysis of mRNAs from a series of human cell
lines has revealed a complex pattern of transcription of the
met protooncogene (Park et al., 1986). Many cell lines,
including a human fibroblast cell line, contain a single 9.0 kb
mRNA species. Other cell lines such as the CaLu-I lung
tumour line contain both 9.0kb and 7.0 kb mRNAs while
the most complex pattern of transcription of the normal met
gene is present in MNNG-HOS cells and in the parent HOS
cell line, which both contain 9.0kb, 7.0 kb and 6.0kb
mRNA species. Most B-cell and T-cell tumour lines do not
contain detectable levels of met transcripts.
Antibodies raised against synthetic peptides corresponding
to the carboxyl terminus of the predicted met gene product
have been used to detect proteins encoded by the activated
and normal met genes (Park et al., 1986b; Tempest et al.,
1986b). The results of the studies by Park et al. (1986b)
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demonstrated that the activated met gene present in
MNNG-HOS cells encodes a protein in the size range 60-
65kD that catalyses autophosphorylation on tyrosine resi-
dues when incubated in the presence of [y-32P]ATP.
160kD, 140kD and 110kD proteins were immunoprecipi-
tated from cells that expressed the normal met gene. How-
ever, when the immunoprecipitated met protein was
incubated in the presence of [y-32P]ATP only the 140kD
met protein (pI40me') was labelled by autophosphorylation.
Similar results were obtained by Tempest et al. (1986b),
although in this particular study of low level ofphosphoryla-
tion of a 165kD protein, which probably corresponds to the
160 kD protein detected by Park et al. (1986b), was also
observed.
As a first step in determining whether alterations in met
can be implicated in the induction of human tumours we
have used antipeptide antibodies to examine met protein
kinase activity in a series of human tumour cell lines. In
addition, to help understand the large quantitative and
qualitative variations in met kinase activity observed in these
experiments, we have used SDS-polyacrylamide gel electro-
phoresis to examine the structure of the mature met protein.
Materials and methods
Cell lines
Human MNNG-HOS and HOS cells were obtained from Dr
J. Rhim, A431 and C-4I human cervical carcinoma cells,
HL60 human promyelocytic leukaemia cells, and CaLu-1
human lung carcinoma cells were obtained from the
American Type Culture Collection. Daoy human medullo-
blastoma cells were provided by Dr P. Jacobsen. All cell
lines were grown in Dulbecco's modified Eagle's medium
containing 10% foetal calf serum, penicillin (500ygml-1),
streptomycin (50ygml-1) and neomycin (50pgml-1) in an
atmosphere containing CO2 (10%, v/v).
Antibodies
The preparation of antipeptide antibodies that recognise the
met protein has been described previously (Tempest et al.,
1986b). Briefly, a peptide with the sequence
VDTRPASFWETS that corresponds to the amino acid
sequence at the C-terminal end of the predicted met gene
product was synthesised. The peptide was coupled to keyhole
limpet haemocyanin and the conjugate used to immunise
rabbits. Antipeptide antibodies were purified by chromato-
graphy on an affinity column of immobilised synthetic
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peptide before use. The anti-EGF receptor antibody was
purchased from Amersham International.
Immunoprecipitation and kinase assays
Cells were washed in phosphate-buffered saline (PBS) and
solubilized in 1 ml of lysis buffer (50 mM Tris HCl pH7.6,
150mM NaCl, 100 mM benzamidine, 1% Nonidet-P40, 1 mM
EGTA, 50,igml -1 phenylmethylsulphonyl fluoride,
10 jgml-l aprotinin and 5pgml-1 trypsin inhibitor).
Lysates were clarified by centrifugation at 12,000 g for
10min at 4°C. Protein content of the cleared lysates was
determined with the Biorad protein assay reagent. Samples
for protein estimation were first extracted with isoamyl
alcohol and chloroform in order to remove Nonidet P-40.
Antibody/Protein A-Sepharose complexes were prepared
by incubating 20pl protein A-Sepharose CL-4B (Pharmacia)
(50%, v/v, in PBS) with an equal volume of PBS containing
1 Mg of antibody for 20min at 22°C. The washed anti-
body/Protein A-Sepharose complexes were then incu-
bated with aliquots of cell lysates containing equal
amounts of protein either in the absence or presence of
1 mM immunising peptide for 16 h at 4°C. To assay for
kinase activity each immunoprecipitate was washed five
times with HNTG (20mM Hepes pH7.5, 150mM NaCl,
0.1% Triton X-100, 10% glycerol) and resuspended in 40tul
HNTG containing 5mM MnCl2 and 3-5pCi [y- 32P]ATP
(5,000 Cimmol-1, Amersham International). The mixture
was then incubated at 22°C for 15 min. When the samples
were to be analysed under reducing conditions the reactions
were terminated by the addition of an equal volume 2X
sample buffer (125mM TrisHCI pH6.8, 4% SDS, 20%
glycerol, 0.02% bromophenol blue) containing 10% 2-
mercaptoethanol. Precipitated proteins were solubilized by
boiling for 3 min before being subject to electrophoresis
through 5-10% polyacrylamide gels containing SDS
(Laemmli, 1970). Samples that were analysed under non-
reducing conditions were treated in a similar manner except
that 2-mercaptoethanol was omitted. To detect phosphory-
lated proteins the gels were fixed in 10% acetic acid, dried
and subject to autoradiography at -70°C for 0.5-6h using
Fuji RX film.
Results
Variations in met protein kinase activity
In these experiments antipeptide antibodies raised against a
synthetic dodecapeptide corresponding to the carboxyl termi-
nus of the predicted met gene product have been used to
immunoprecipitate products of the met gene from several
human tumour cell lines. The met kinase activity was then
detected by incubating the immunoprecipitated met protein
in the presence of [y-32P]ATP under conditions that nor-
mally result in autophosphorylation of pl4Ome, (Tempest et
al., 1986b). The cell lines examined in these studies include a
promyelocytic cell line (HL60), a medulloblastoma cell line
(Daoy), a lung carcinoma cell line (CaLu-l), an osteosar-
coma cell line (HOS) and two cervical carcinoma cell lines
(A431 and C-41). The most striking feature of the results
obtained in these analyses was the considerable quantitative
and qualitative variations in met kinase activity within this
modest series of human tumour cell lines. As expected no
kinase activity was detected in HL60 cells (result not shown),
which does not contain detectable levels of met transcripts
(Park et al., 1986a). In agreement with the results of our
previous study (Tempest et al., 1986b) similar levels of
autophosphorylation of pl40met was observed in immuno-
precipitates of HOS cells and MNNG-HOS cells, while in
addition phosphorylation of the 60 kD protein encoded by
the activated human met gene was found in immunoprecipi-
tates of MNNG-HOS cells (Figure 1). In a preliminary
study Park et al. (1986) observed high levels of phosphoryla-
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Figure 1 Autoradiograph of proteins that have been immuno-
precipitated with met antipeptide antibodies, incubated in vitro
with [y -32P]ATP and analysed with SDS-polyacrylamide gel
electrophoresis under reducing conditions. HOS, a human osteo-
sarcoma cell line; MNNG-HOS, a chemically-transformed
human cell line; CaLu-1, a human lung carcinoma cell line; C-41,
a human cervical carcinoma cell line; and Daoy, a human
medulloblastoma cell line. The molecular masses are indicated in
kD.
tion of p140ne7 in immunoprecipitates from CaLu-1 cells and
a complex pattern of phosphorylation in immunoprecipitates
from C-41 cells. In the present study we have confirmed these
observations and, in addition, have demonstrated that the
level of phosphorylation of pl40me1 in immunoprecipitates
from A431 cells is approximately 10-fold higher than that
found in experiments with MNNG-HOS cells (Figure 2). In
control experiments precipitation of met proteins from all
cell lines was diminished when immunoprecipitations were
carried out in the presence of an excess of immunizing
peptide (for example see Figures 2 and 5).
A remarkable pattern of phosphorylation was observed
when met protein immunoprecipitated from the Daoy medul-
loblastoma cell line was incubated with [y 32P]ATP. There
was no phosphorylation of p140me'; instead a high level of
phosphorylation of a 132 kD protein was detected (Figures 1
and 2). The simplest interpretation of these results is that
Daoy cells possess an abnormal met protein that is slightly
smaller than the present in other cell lines. To determine
whether this alteration was specific to the met protein or
whether it reflects, for example, a more general alteration in
the ability of Daoy cells to process membrane receptor
proteins we have examined the properties of the epidermal
growth factor (EGF) receptor present in Daoy cells. Immuno-
precipitated EGF receptor that had been incubated in vitro
with [y - 32P]ATP to label the protein by autophosphoryla-
tion was subject to electrophoresis in SDS-polyacrylamide
gels. The results (Figure 3) showed that EGF receptor
present in Daoy cells has the same molecular weight as that
present in A431, a cell line that overexpresses the normal
EGF receptor protein (Fabricant et al., 1977).met PROTEIN KINASE ACTIVITY IN HUMAN TUMOURS 5
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Figure 2 Autoradiograph of proteins that have been immuno-
precipitated with met antipeptide antibodies either in the presence
(I+) or absence (I-) of immunizing peptide, incubated in vitro
with [y -32P]ATP and analysed by SDS-polyacrylamide gel
electrophoresis under reducing conditions. A431, human cervical
carcinoma cell line; MNNG-HOS, chemically-transformed
human cell line; CaLu- 1, human lung carcinoma cell line; and
Daoy, a human medulloblastoma cell line. The molecular masses
of the standards are indicated in kD.
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Figure 3 Immunoprecipitation of the EGF receptor from A431
cells (lanes a and b) and Daoy cells (lanes c and d). EGF
receptor was immunoprecipitated from cell lysates, autophos-
phorylated by incubation with [y -32P]ATP and subject to
electrophoresis on SDS-polyacrylamide gels. The molecular mass
of the EGF receptor is indicated in kD.
Structure of the met protein
Examination of the predicted amino acid sequence of the
human met protein (Park et al., 1987) revealed the interest-
ing sequence Lys-Arg-Lys-Lys-Arg-Ser 303 amino acids from
the amino terminus. This basic amino acid sequence is
similar to the sequence Arg-Lys-Arg-Arg-Ser found at the
cleavage site of the insulin receptor precursor (Ullrich et al.,
1985) and to the sequence Arg-Lys-Arg-Arg-Asp found at
the cleavage site of the precursor of the insulin-like growth
factor I receptor (Ullrich et al., 1986). A more detailed
comparison of the basic amino acid sequence present in the
human and mouse met proteins and those present in the
precursor of the insulin and insulin-like growth factor I
receptors is shown in Figure 4. In the precursors of the
insulin and insulin-like growth factor I receptors this is the
p-subunit
Arg-Lys-Arg-Arg -Ser
Arg-Lys-Arg-Arg-GSu
Lys-Arg-Arg-Lys -Arg-Ser
Lys-Arg-Lys-Lys-Arg -Ser
Figure 4 Potential proteolytic cleavage site of the met protein.
The amino acid sequences at the proteolytic cleavage sites used
for the processing of the precursors of the insulin receptor and
insulin-like I growth factor receptor into a and ,B subunits are
compared to amino acid sequences present in the predicted
mouse and human met gene products. Amino acids 720-724 of
the precursor of the insulin receptor (Ullrich et al., 1985) and
amino acids 707-711 of the precursor of the insulin-like growth
factor I receptor (Ullrich et al., 1986) are compared to amino
acids 302-307 of the mouse met protein (A.M.-L. Chan, H.W.S.
King and C.S. Cooper, unpublished observation) and to amino
acids 303-308 of the human met protein (Park et al., 1987). The
amino terminal of the /3 subunits of the insulin receptor and
insulin-like growth factor I receptor are indicated by the arrow.
site for cleavage of the precursor into the a and ,B subunits,
which in the mature receptor are joined by disulphide bonds
in an ocf2#2 configuration (for example see Ronnett et al.,
1984). Cleavage of the basic sequence present in the product
of the human met gene would generate an N-terminal
peptide of 283 amino acids that might become associated
with the remaining membrane bound portion of the met
proteins in a manner similar to that observed for the insulin
and insulin-like growth factor I receptors. To test the
possibility that the product of the met gene exists as a
multisubunit complex we have subjected met protein that
had been 32P-labelled in vitro by autophosphorylation to
electrophoresis in denaturing SDS-polyacrylamide gels
under either reducing or non-reducing conditions. When the
proteins were analysed under conditions that should convert
multisubunit proteins joined by disulphide bonds to their
component subunits (reducing conditions) the usual 140kD
met protein was observed (Figure 5). However when the
proteins were analysed under conditions that should not
dissociate multisubunit proteins joined by disulphide bonds
(non-reducing conditions) a 165 kD protein was detected
(Figure 5). When considered together these observations
suggest that the mature met protein may exist as an a4
complex in which the 140 kD # subunit is joined to a
smaller, 25kD, a subunit, although the proposed a-subunit
has not been detected directly in these experiments.
Discussion
In this study we have found considerable diversity of met
protein kinase activity amongst a small group of human
tumour cell lines. High levels of protein kinase activity were
found in immunoprecipitates of met protein from C-41 and
A431 cervical carcinoma cells, Daoy medulloblastoma cells
and CaLu-I lung carcinoma cells while only low levels of
protein kinase activity were found in immunoprecipitates of
met protein from HOS cells. The patterns of protein phos-
phorylation found in C-4I cells and in Daoy cells are
complex. Phosphorylation of several proteins was observed
when immunoprecipitated met protein from C-41 cells was
incubated with [y-32P]ATP while similar analyses of met
proteins from Daoy cells revealed high levels of phosphory-
lation of a 132 kD protein but no phosphorylation of
pl40met. Although a firm link has not been established it is
interesting to speculate that these alterations in met kinase
activity may, in some way, be implicated in cell
transformation.
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Figure 5 Analysis of p1401?w in SDS-polyacrylamide gels under
reducing and non-reducing conditions. The met proteins were
immunoprecipitated from cell extracts of the HOS human osteo-
sarcoma cell line in the absence (I-) or presence (I+) of
immunizing peptide and incubated with [y -32P]ATP to label
p1401?w by autophosphorylation. Radiolabelled proteins were
detected by autoradiography. The immunoprecipitated proteins
were solubilized by boiling either in the presence (reducing
conditions) or absence (non-reducing conditions) of 2-mercapto-
ethanol and subject to electrophoresis in 5.75% SDS-polyacryl-
amide gels. The molecular mass of the standards are indicated in
kD.
In a previous study, analysis of the met proteins immuno-
precipitated from HOS cells that had been metabolically
labelled with 35S-methionine revealed that the pattern of
expression of the met gene was complex (Park et al., 1986b).
Proteins with apparent molecular weights of 160 kD, 140 kD
and 110kD were detected but the relationship between these
proteins was not determined. For example it was not known
whether the smaller polypeptides are derived from the larger
proteins by proteolytic cleavage or whether they represent
completely independent products. The protein encoded by
the human met gene possesses the amino acid sequence Lys-
Arg-Lys-Lys-Arg-Ser that is similar to the amino acid
sequence found at the site of proteolytic cleavage site of the
precursors at the insulin and insulin-like I growth factor
receptors into a and f subunits (Ullrich et al., 1985, 1986)
which in the mature receptors are joined by disulphide bonds
in an a2f2 configuration. Allowing for increase in the size of
the met protein that may result from post-translational
glycosylation the predicted sizes of the met protein before
and after cleavage at this position (respectively, 154kD and
122kD) are in reasonable agreement with the sizes of the
two largest met proteins, pl6Omel and p140me'. Thus, it is
possible that pm40me, is derived from pl60meI by proteolytic
cleavage at this stretch of basic amino acids.
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Figure 6 Possible structure of the mature met protein (MET) is
compared with the structure of the epidermal growth factor
receptor (HER), the insulin receptor (HIR) and the platelet
derived growth factor receptor (PDGF-R). The proposed a,B
structure of the met protein is generated by cleavage of the
amino acid sequence Lys-Arg-Arg-Lys-Arg-Ser followed by asso-
ciation of the N-terminal peptide (oc subunit) with the remaining
membrane bound portion of the met protein (# subunit). Cys-
teine-rich chains are shown as solid bases; other cysteine residues
in the extracellular domain are shown as solid circles. Tyrosine
kinase domains are shown as open boxes.
Evidence that the met protein can exist as an a,B complex
in which the two subunits are joined by disulphide bonds
was obtained when met protein that had been 32P-labelled
by autophosphorylation was subject to SDS-polyacrylamide
gel electrophoresis under non-reducing conditions. The
pl40net, which is the major protein 32P-labelled in these
experiments, had an apparent size of 165 kD when run in a
non-reducing gel, indicating that in the mature met protein
the pl40?mt (designated the P subunit) may be associated
with a smaller, 25 kD, a subunit. Although we have not
detected the a subunit directly in these analyses, by analogy
with the structure of the insulin and insulin-like I growth
factor receptors we would expect the oe subunit to be derived
from the N-terminal met polypeptide that is formed follow-
ing proteolytic cleavage at amino acid sequence Lys-Arg-
Lys-Lys-Agr-Ser. The proposed structure of the a/I met
complex is shown in Figure 6 where its structure is com-
pared with those of other classes of growth factor receptors
that possess an intracellular protein tyrosine kinase domain.
In conclusion, we have demonstrated that considerable
quantitative and qualitative variation in met kinase activity is
found among human tumour cell lines and we have provided
evidence that the met protein may exist as an ac/ complex in
which the two subunits are joined by disulphide bonds. In
future studies we hope to investigate the significance of this
large variation in met kinase activity and to learn more
about the structure of the mature met protein.
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